Cencora, Inc. (COR) has a MoatMap StockRank of 51/100 based on Quality (48/100), Value (37/100), and Momentum (52/100) factor scores. The current signal is HOLD. Cencora is a premier quality compounder operating in a highly consolidated US pharmaceutical distribution oligopoly. It exhibits incredible scale economics shared with customers, high returns on capital, and an unbreakable moat. The business is highly resilient to macro shocks and is currently riding a powerful tailwind from the volume growth of high-value specialty medicines and GLP-1 therapies, offering highly visible, low-risk cash flow growth.
Cencora (formerly AmerisourceBergen) is a leading global pharmaceutical sourcing and distribution services company, connecting drug manufacturers with healthcare providers worldwide. As one of the "Big Three" U.S. pharmaceutical distributors, it commands significant market share and benefits from immense scale, sophisticated logistics, and critical supply chain integration. Its robust network and high barriers to entry provide a strong competitive moat in the essential healthcare supply chain.
| Price | $279.57 |
| Market Cap | $52.1B |
| P/E (TTM) | 20.70 |
| P/E (Forward) | 13.67 |
| Price/Book | 15.48 |
| Return on Equity | 107.1% |
| Return on Invested Capital | 14.3% |
| Debt/Equity | 420.99 |
| Gross Margin | 3.8% |
| Operating Margin | 1.7% |
| Revenue Growth | 3.8% |
| Dividend Yield | 0.9% |
| Free Cash Flow | $-318M |
Cencora, Inc. operates in the Medical Distribution industry, part of the Healthcare sector (United States).